Griffin nct02874742
WebNov 23, 2024 · In the primary analysis of the phase 2 GRIFFIN trial (NCT02874742) in autologous stem cell transplant (ASCT)-eligible … WebDec 14, 2024 · Findings from the extended 2-year follow-up of the phase 2 GRIFFIN trial (NCT02874742) that were presented during the 63rd American Society of Hematology Annual Meeting and Exposition revealed continued deep and durable responses for patients with transplant-eligible newly diagnosed multiple myeloma when daratumumab …
Griffin nct02874742
Did you know?
WebNov 5, 2024 · Introduction: DARA, a human IgGκ monoclonal antibody targeting CD38, is approved as monotherapy and in combination with standard-of-care regimens for relapsed/refractory multiple myeloma and … WebDec 11, 2024 · About the GRIFFIN Study The Phase 2 GRIFFIN (NCT02874742) study evaluated the investigational regimen of DARZALEX ® in combination with VRd and …
WebDec 23, 2024 · DARA is approved for NDMM and previously treated MM. In the primary analysis of the phase 2 GRIFFIN trial (NCT02874742) in autologous stem cell transplant (ASCT)-eligible NDMM pts (median follow-up, 13.5 mo), DARA plus RVd (D-RVd) improved the rate of stringent complete response (sCR) by the end of post-ASCT consolidation … WebFeb 4, 2024 · Feb 4, 2024. Saad Z. Usmani, MD. Updated results from the GRIFFIN study, which combined daratumumab with RVd in patients with transplant-eligible newly …
WebJan 11, 2024 · The 5-year survival rate for multiple myeloma has risen by nearly 10% over the past decade, and is now at a 56%, largely due to novel agents and their combinations. 21 Over the next decade we will ... WebNov 15, 2024 · Introduction: GRIFFIN (NCT02874742) is a multicenter, randomized, open-label, active-controlled, phase 2 study comparing daratumumab in combination with bortezomib, lenalidomide and dexamethasone (D-RVd) vs RVd in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM). In the primary analysis (median …
WebNov 5, 2024 · The phase 2 randomized GRIFFIN study (NCT02874742) evaluates frontline DARA in combination with lenalidomide, bortezomib, and dexamethasone (D-RVd) in transplant-eligible NDMM. In the primary analysis, ... In GRIFFIN, 93.7% of D-RVd pts and 98.8% of RVd pts reached the minimum institutional CD34 + threshold to perform a …
WebFeb 4, 2024 · New data from the phase 2 GRIFFIN trial showed sustained, deep responses in the study population [1]. In the phase 2 GRIFFIN trial (NCT02874742), patients with … girish extension boardWebAug 20, 2024 · This trial was registered at www.clinicaltrials.gov as #NCT02874742. Subjects: Clinical Trials and Observations, Lymphoid … girish finance services thaneWebDec 7, 2024 · About the GRIFFIN Study 4 The Phase 2 GRIFFIN ( NCT02874742 ) study has enrolled and treated more than 200 adults ages 18-70 years with NDMM and who … girish gaitonde net worthWebApr 13, 2024 · The phase 2 GRIFFIN study (ClinicalTrials.gov Identifier: NCT02874742) evaluated the addition of the anti-CD38 monoclonal antibody daratumumab to RVd (D-RVd) induction and consolidation with ... funbags urban dictionaryWebLearn about Equinix DC2 carrier-neutral data center, located at 21715 Filigree Court, Ashburn, VA. See our interconnection options, certifications and more. fun bagel factsWebDec 7, 2024 · About the GRIFFIN Study 3 The Phase 2 GRIFFIN (NCT02874742) study has enrolled and treated more than 200 adults ages 18-70 years with NDMM and who are eligible for high-dose therapy/autologous ... girish githubWebFeb 4, 2024 · New data from the phase 2 GRIFFIN trial showed sustained, deep responses in the study population [1]. In the phase 2 GRIFFIN trial (NCT02874742), patients with newly diagnosed MM, eligible for high-dose therapy and autologous haematopoietic cell transplantation (HCT) were randomised 1:1 to receive daratumumab plus RVd (n=104) … funbags cornhole